raloxifene hydrochloride has been researched along with metallothionein in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abbondanza, C; Bellastella, A; Bellastella, G; Chieffi, P; De Bellis, A; De Rosa, C; Della Ragione, F; Maione, L; Prezioso, D; Rossi, V; Sinisi, AA; Visconti, D | 1 |
1 other study(ies) available for raloxifene hydrochloride and metallothionein
| Article | Year |
|---|---|
Raloxifene induces cell death and inhibits proliferation through multiple signaling pathways in prostate cancer cells expressing different levels of estrogen receptor α and β.
Topics: Antineoplastic Agents, Hormonal; Apoptosis; Caspase 3; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dihydrotestosterone; Dose-Response Relationship, Drug; Enzyme Activation; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Gene Expression Regulation, Neoplastic; Humans; Male; Metallothionein; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Raloxifene Hydrochloride; Receptors, Thrombin; RNA, Messenger; Selective Estrogen Receptor Modulators; Signal Transduction; Time Factors; Transcription, Genetic | 2011 |